Uric acid (UA) is the end product of purine metabolism in humans due to the loss of uricase
activity by various mutations of its gene during the Miocene epoch, which led to humans …

Childhood-onset systemic lupus erythematosus (cSLE) is a rare, multisystem and potentially
life-threatening autoimmune disorder with significant associated morbidity. Evidence-based …

Hyperuricemia and gout, the clinical manifestation of monosodium urate crystal deposition,
are common in patients with chronic kidney disease (CKD). Although the presence of CKD …

Gout, a disease recognized since antiquity, has increased in prevalence in recent years and
the clinical profile of this disease has become increasingly complex, owing to large numbers …

Objective Allopurinol is the most commonly used urate‐lowering therapy in gout. Allopurinol
hypersensitivity syndrome (AHS) is a rare but potentially fatal adverse event. Dosing …

Objective: To investigate and compare the prevalence, comorbidities and management of
gout in practice in the UK and Germany. Methods: A retrospective analysis of patients with …

Objective To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the
anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in …

Gout is the most common inflammatory arthritis and one in which pathogenesis and risk
factors are best understood. One of the treatment objectives in current guidelines is 'cure' …

Objective To assess the epidemiology of gout and hyperuricaemia in the Italian general
population during the years 2005–2009. Methods Using the Italian primary care database …

Introduction Many doctors believe that patients with gout are unwilling to receive urate-
lowering therapy (ULT) and blame them for poor adherence to management. Objective To …